What Happened?
, -based ImmunoPrecise-Antibodies Resigned Brad McConn as Chief Financial Officer
Date of management change: September 19, 2023
, -based ImmunoPrecise-Antibodies Resigned Brad McConn as Chief Financial Officer
IPA is a progressive, scientific Contract Research Organization (CRO) recently ranked by one of the pharmaceutical industry`s most trusted, independent market research sources with the highest competitive score, for its antibody service portfolio.1 The company represents a HUB of biotherapeutic intelligence that includes a hybrid of experts and technologies, in the science and business of bioplatform-based discovery. We provide highly specialized full-continuum therapeutic antibody discovery, development, and out-licensing services [Talem] —with advanced omics and complex intelligence technology [LENSai] that provide greater efficiency and accuracy than ever before. Our mission is to provide our pharmaceutical customers with a HUB of the most advanced intelligence and technology to treat disease, bar none. Our goal — is to improve the specificity of biotherapeutics by unlocking the language of the genome.
Brad McConn is Chief Financial Officer at ImmunoPrecise Antibodies. Previously, Brad held various senior HR leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Fraund Markus, Shepard Amy, Reeves Rachel, Miras Thierry, Wright Rebecca, Ryan Paul, Kilguss Matt, Gutierrez Barbara, Miller Yvonne, Clements Sue, Magrinat Mary
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.